Main content

EFV: The Initial Characterization of a Novel Mono-ADP-ribosyltransferase Toxin

Show simple item record

dc.contributor.advisor Merrill, Rod Reid-Taylor, Robert 2015-02-09T16:16:26Z 2015-02-09T16:16:26Z 2015-02 2014-12-19 2015-02-09
dc.description.abstract EFV is a novel mART toxin from Enterococcus faecalis V583, a vancomycin-resistant pathogen. EFV was shown to target actin as a substrate for its transferase reaction, suggesting a Type IV mART. However, EFV was also shown to be highly toxic to both eukaryotic and prokaryotic cells, suggesting that it may act on more than one substrate. This toxicity could be overcome by the production of a catalytic variant, EFVE461A, which was overexpressed and purified from E. coli. This protein was stable and properly folded. EFVE461A demonstrated glycohydrolase activity with a kcat of 0.06 ± 0.003 s-1. Several novel inhibitors of EFV have been characterized, including one that has been shown to inhibit another actin-targeting mART toxin. This would be the first instance of a potential inhibitor for the Type IV toxins. Characterization of EFV will expand our understanding of the mART family, in particular the Type IV toxin subgroup. en_US
dc.language.iso en en_US
dc.title EFV: The Initial Characterization of a Novel Mono-ADP-ribosyltransferase Toxin en_US
dc.type Thesis en_US Molecular and Cellular Biology en_US Master of Science en_US Department of Molecular and Cellular Biology en_US
dc.rights.license All items in the Atrium are protected by copyright with all rights reserved unless otherwise indicated.

Files in this item

Files Size Format View
ReidTaylor_Rob_201502_Msc.pdf 1.812Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record